´ëÇÑ°£¾ÏÇÐȸ Á¦13Â÷ Á¤±âÇмú´ëȸ : 2019-02-15±³À°ÀÏÀÚ : 2019-02-15
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º
±³À°ÁÖÁ¦ :
´ëÇÑ°£¾ÏÇÐȸ Á¦13Â÷ Á¤±âÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑ°£¾ÏÇÐȸ
´ã´çÀÚ : ÀÌÁøÈ °úÀå
¿¬¶ôó : 02-373-1005
À̸ÞÀÏ :
jhlee@hbni.co.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Æò»ýȸ¿ø 4¸¸, ºñȸ¿ø5¸¸, Àü°øÀÇ/±ºÀÇ°ü/°£È£»ç 2¸¸ (»çÀüµî·Ï)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 08:30~08:40 Basic Research in HCC ¹ÌÁ¤(¹ÌÁ¤)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 08:40~08:50 Epidemiology, Staging System, and Prediction ¹ÌÁ¤(¹ÌÁ¤)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 08:50~09:00 Clinical Trial, Translational Research, Meta-Analysis ¹ÌÁ¤(¹ÌÁ¤)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 09:00~09:10 Interventional Treatment ¹ÌÁ¤(¹ÌÁ¤)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 09:10~09:20 Surgical Treatment ¹ÌÁ¤(¹ÌÁ¤)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 09:20~09:30 Radiotherapy and Systemic Treatment ¹ÌÁ¤(¹ÌÁ¤)
ÈÞ½Ä 02-15 ±×·£µåº¼·ë 09:30~09:50 ÈÞ½Ä ()
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 09:50~10:15 Histological and Molecular Heterogeneity: Where We Are? ¿ìÇö±¸(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 10:15~10:40 Biomarker Based Therapy: Are There Available Weapons? ±è¿µ¼ö(¼¿ï´ë ÀÇ°øÇÐ)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 10:40~11:05 Radionomics in Oncology: Is It Another Tool to Decipher Heterogeneity of HCC? Á¤¿ì°æ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 11:05~11:30 Understanding the Characteristics of Combined HCC and CCC: New WHO Classification ¹Ú¿µ³â(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 02-15 ±×·£µåº¼·ë 11:30~11:40 ÈÞ½Ä ()
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 11:40~12:40 Luncheon Symposium ÇѼº±¸(¼¿ïÀÇ´ë)
ÈÞ½Ä 02-15 ±×·£µåº¼·ë 12:40~12:50 ÃÑȸ ()
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 12:50~13:20 Special Lecture Shoji Kubo(Osaka City Univ.)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 13:30~13:55 Better Understanding the Concept of Immuno-Oncologic Research ¹Ú¼öÇü(KAIST)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 13:55~14:20 First Line Systemic Therapies: Who Is the Best Player? Richard S. Finn(Geffen School of Medicine at UCLA)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 14:20~14:45 Second Line Systemic Therapies: Who Is the Best Savior? ¹ÚÁß¿ø(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 14:45~15:10 When We Switch to Systemic Therapy after Loco-Regional Treatment Failure: Definition and Best Timing Sadahisa Ogasawara(Chiba Univ.)
±³À°½Ã°£ 02-15 ±âŸÀå¼Ò 15:10~16:10 Poster Presentation äÅÃÀÚ ¿Ü()
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 16:10~16:35 Robotic Surgery for Hepatectomy: Comparison with Laparoscopic Approach ÃÖ±âÈ«(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 16:35~17:00 Recent Advances in Thermal Ablation for HCC: Update of RFA and Emerging New Energy Source À̹οì(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 17:00~17:25 Transarterial Therapy: Newer Is Better? õȣÁ¾(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 02-15 ±×·£µåº¼·ë 17:25~17:50 Particle Therapy: How Far Have We Come? ±èÅÂÇö(±¹¸³¾Ï¼¾ÅÍ)